FDA Liked What It Saw In Kalydeco’s Development Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Agency reviewers looked favorably upon the pivotal trials’ primary efficacy endpoint and low drop-out rate, as well as the overall quality of the NDA submission.